Trellus Health PLC ( ($GB:TRLS) ) has shared an update. Trellus Health PLC has signed a 12-month contract with a leading global clinical research ...
Inflammatory bowel disease (IBD) is a chronic condition that causes inflammation in the digestive system. It affects about 10 ...
Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...
To address the specific challenges faced by older adults with inflammatory bowel disease (IBD), UCSF Health created the UCSF ...
Average dietary fiber intake is lower among patients with active vs inactive inflammatory bowel disease, particularly among ...
GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.
San Francisco-based UCSF Health opened a specialty clinic in July for adults 65 and older with inflammatory bowel disease. The UCSF IBD Longevity Clinic is led by gastroenterologist Kendall Beck, MD, ...
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in ...
The Implantable Cell Therapy AVB-114 Demonstrated Favorable Safety and Effectiveness in the Phase II Trial for Crohn's Perianal Fistulas - NEWARK, Del., Oct. 29, 2025 /PRNewswire/ -- Avobis Bio LLC, a ...
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi has initiated a new clinical study titled ‘A Multinational, ...
Upadacitinib is now approved for IBD patients unsuitable for TNF blockers after one systemic therapy, broadening treatment options. Clinical trials show upadacitinib's efficacy in achieving remission ...
A biomedical researcher combining advanced mouse models with human-based and computational approaches explains why we can’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback